Circulating cell-free DNA (ccfDNA) can be isolated from plasma. In addition, ccfDNA allows secondary mutations to be monitored over time. The QIAact Lung Plasma Track Panel enables analytical detection of secondary lung cancer mutations present at ≥0.1% variant allele frequency in ccfDNA from plasma.
The QIAact Lung Plasma Track Panel allows the detection of sensitizing and secondary mutations described in the literature for lung cancer from ccfDNA samples derived from plasma. This allows a comprehensive tracking of all variants from liquid biopsy as well as matching to variants found in tumor tissue. In total, more than 250 mutations are included. Analytical sensitivity for the panel has been demonstrated at ≥0.1% allele frequency.
The QIAact Lung Plasma Track Panel can only be used with the GeneReader NGS System. This panel, together with other QIAGEN products, is integrated into a complete pre-optimized workflow, including sample collection, variant detection, interpretation and reporting.
Research Use Only product